# Aosaikang Pharmaceutical

Source: https://onco.cc/companies/aosaikang-pharmaceutical/  
OnCo record `aosaikang-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours.

## Summary

Aosaikang Pharmaceutical is a research-driven pharmaceutical manufacturer listed in Shenzhen that develops, produces and sells active ingredients and finished medicines in gastroenterology, oncology, anti-infectives and chronic disease. Its site cites China's first injectable proton pump inhibitor as a flagship product and lists clinical-stage innovative candidates including molecular glue degraders. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT04632108 (phase 1/2, A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor...), NCT04143607 (phase 3, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metast...) and NCT07109531 (phase 3, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Loc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Jiangsu Aosaikang Pharmaceutical; ASK Pharm; 奥赛康药业
- Tags: ctgov-sponsor
- HQ: Nanjing
- Type: pharma
- Website: https://www.ask-pharm.com/
- Ticker: SZSE:002755

## Sources

- Official website: https://www.ask-pharm.com/
- ClinicalTrials.gov: trials led by Aosaikang Pharmaceutical: https://clinicaltrials.gov/search?lead=Jiangsu%20Aosaikang%20Pharmaceutical%20Co.%2C%20Ltd.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Limertinib](https://onco.cc/drugs/limertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- trials: [A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04632108/), [ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04143607/), [ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy](https://onco.cc/trials/nct07109531/)

---
JSON: https://onco.cc/api/v1/entities/aosaikang-pharmaceutical.json